[Primary detection of malignant mesothelioma of the tunica vaginalis testis using the BMA-120 monoclonal antibody].
Malignant mesothelioma of the tunica vaginalis testis is an extremely rare tumor, with only 40 cases previously described in the literature. Treatment consists of inguinal orchiectomy with close-follow up [1]. Asbestose exposure, trauma and hydrocele have been implicated as risk factors. We describe a histopathological examination with the BMA antibody (Behring, Marburg, Germany) and the Lu-5 antibody (Hoffmann-La Roche, Basel, Switzerland). Furthermore, we describe the patient's history and the management according to preceding reports in the literature.
Biermann
C W
CW
Urologische Universitätsklinik, Ruhr-Universität Bochum, Marienhospital Herne.
Moch
H
H
Gasser
T C
TC
de Riese
W
W
Rutishauser
G
G
D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000473:pathology* / Q000601:surgery; D009919:Orchiectomy; D013736:Testicular Neoplasms / Q000473:pathology* / Q000601:surgery; D013737:Testis / Q000473:pathology
D014408:Biomarkers, Tumor
Erstmaliger Nachweis eines malignen Mesothelioms der Tunica vaginalis testis mit Hilfe des mononuklearen Antikörpers BMA-120.